PolyPid assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of PolyPid (PYPD) with a Buy rating and $11 price target PolyPid is a platform technology drug delivery company, with a “unique and novel” PLEX technology, which can be applied to a broad range of therapeutics, including small molecules, proteins, peptides and nucleic acids, the analyst tells investors in a research note. The firm says the stock is currently valued on its lead product D-PLEX100 alone, “which the market appears to assign a lower probability of success than we believe it deserves.”